• Mashup Score: 0
    Prostate cancer: small non-coding RNAs in urinary exosomes - 4 year(s) ago

    Laurence Klotz, MD, Sunnybrook Health Sciences Centre, Odette Cancer Centre, University of Toronto, Toronto, Canada, discusses the use of small…

    Source: VJOncology
    Categories: Hem/Oncs
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      VIDEO: Prostate cancer: small non-coding RNAs in urinary exosomes w/ Laurence Klotz of @Sunnybrook: https://t.co/iviHqc5DcF #GU20 @ASCO @ASTRO_org #UroSoMe #UroOnc #PCsm #ProstateCancer #OncoAlert

  • Mashup Score: 0
    Quality of Life in the Treatment of mHSPC: The STAMPEDE Trial - Hannah Rush - 4 year(s) ago

    Hannah Rush joins Alicia Morgans discussing the quality of life outcomes we have seen from patients receiving docetaxel or abiraterone in the STAMPEDE trial. STAMPEDE is a multi-arm, multi-stage trial investigating various therapeutic strategies for the management of locally advanced or metastatic hormone-naïve prostate cancer. In recent years, both docetaxel and abiraterone have been shown to…

    Source: UroToday
    Categories: Urology
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Quality of life in the treatment of #mHSPC: The #STAMPEDE trial. @HannahR08378281 @ucl joins @CaPsurvivorship @NUFeinbergMed to discuss treatment considerations for newly diagnosed mHSPC patients. #WatchNow on UroToday > https://t.co/8BVx8nanXS @MRCCTU @ASCO #GU20 https://t.co/uG2v03thlp

  • Mashup Score: 1
    Prostate cancer: biomarkers - 4 year(s) ago

    Felix Feng, MD, University of California San Francisco, San Francisco, CA, gives his thoughts on the use of biomarkers in…

    Source: VJOncology
    Categories: Hem/Onc News and Journals
    Tweet Tweets with this article
    • Profile photo of OncoAlert
      OncoAlert

      RT @VJOncology: Prostate cancer: biomarkers w/ @felixfengmd of @UCSFUrology: https://t.co/MRyfICrMEC #GU20 @ASCO @ASTRO_org #UroSoMe #UroOn…

  • Mashup Score: 0
    Immunotherapy with radiotherapy in RCC: is there a benefit? - 4 year(s) ago

    Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, discusses the results of the RADVAX trial (NCT03065179) combining immune…

    Source: VJOncology
    Categories: Hem/Oncs
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      VIDEO: Immunotherapy with radiotherapy in RCC: is there a benefit? w/ Thomas Powles of @QMBCI: https://t.co/UrjXzNUEHA #GU20 @ASCO @ASTRO_org #UroSoMe #UroOnc #KCsm #KidneyCancer

  • Mashup Score: 0
    Blue light cystoscopy for bladder cancer - 4 year(s) ago

    Sima Porten, MD, MPH, FACS, University of California, San Francisco, CA, discusses a study on blue light cytoscopy with cysview…

    Source: VJOncology
    Categories: Hem/Oncs
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      VIDEO: Blue light cystoscopy for #BladderCancer w/ @SimaPorten of @UCSF: https://t.co/UzJ9ME16uC #GU20 @ASCO @ASTRO_org #UroSoMe #UroOnc #BCsm

  • Mashup Score: 1
    Bladder: neoadjuvant immunotherapy & ctDNA - 4 year(s) ago

    Petros Grivas, MD, PhD, University of Washington, Seattle, WA, discusses his research highlights from the 2020 Genitourinary Cancers Symposium, held…

    Source: VJOncology
    Categories: Hem/Onc News and Journals
    Tweet Tweets with this article
    • Profile photo of OncoAlert
      OncoAlert

      RT @VJOncology: Bladder: neoadjuvant immunotherapy & ctDNA w/ @PGrivasMDPhD of @SeattleCCA: https://t.co/VaDRlJJ1gD #GU20 @ASCO @ASTRO_org…

  • Mashup Score: 0
    Bladder: neoadjuvant immunotherapy & ctDNA - 4 year(s) ago

    Petros Grivas, MD, PhD, University of Washington, Seattle, WA, discusses his research highlights from the 2020 Genitourinary Cancers Symposium, held…

    Source: VJOncology
    Categories: Hem/Oncs
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      Bladder: neoadjuvant immunotherapy & ctDNA w/ @PGrivasMDPhD of @SeattleCCA: https://t.co/VaDRlJJ1gD #GU20 @ASCO @ASTRO_org #UroSoMe #UroOnc #BCsm #BladderCancer #oncoalert

  • Mashup Score: 0
    ASCO GU 2020: Chemotherapy/Radiation-Sparing Management Strategies for Early-Stage Germ Cell Tumors - 4 year(s) ago

    ASCO GU 2020, surgical management for early stage non-seminoma, primary RPLND may be preferable for adjuvant management of clinical 1 and clinical stage 2 non-seminomatous germ cell tumors

    Source: www.urotoday.com
    Categories: Urology
    Tweet Tweets with this article
    • Profile photo of urotoday
      urotoday

      Chemotherapy/Radiation-sparing management strategies for early-stage #GermCell tumors. Presentation by Clint Cary MD, MPH @IUMedSchool. Written coverage by @aloktewar @DanaFarber on UroToday > https://t.co/drwk9rIicm @ASCO #GU20 #TesticularCancer https://t.co/lPLmp8vBQz

  • Mashup Score: 0
    Sitravatinib with nivolumab in advanced clear cell RCC - 4 year(s) ago

    Pavlos Msaouel, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the trial (NCT03015740) of sitravatinib combined…

    Source: VJOncology
    Categories: Hem/Oncs
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      VIDEO: Sitravatinib with nivolumab in advanced clear cell RCC w/ @PavlosMsaouel of @MDAndersonNews: https://t.co/Bhwa8CLj4v #GU20 @ASCO @ASTRO_org #UroSoMe #UroOnc #KCsm #KidneyCancer

Load More